secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001664710-23-000028
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Q1 net loss $35.8M, cash $351.4M; KER-012 Phase 2 starts H1 2023
----------------------------------------------------------------------

- Net loss of $35.8M vs $24.2M in Q1 2022; R&D spend $31.1M (+$13.0M YoY) driving pipeline.
- Cash and equivalents $351.4M as of March 31, 2023; runway into Q4 2025.
- Dr. Alpna Seth appointed to board of directors in May 2023.
- KER-012 Phase 2 trial for pulmonary arterial hypertension planned to start H1 2023.
- KER-050 Phase 2 data readouts in MDS and myelofibrosis expected later this year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471023000028/0001664710-23-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471023000028/kros-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001664710-23-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer